arGEN-X huge outperformer in European biotech sector

Thanks to the huge profit of 57 percent since begin this year it's one of the best shares of the biotech sector.

Momentum biotech sector

The sector trades now at 261 times the earnings per share. The sector trades at 36,4 times the book value per share. Since 2012 the sector has a profit of 203 percent and since 2007 a profit of 243 percent.

For this year the company from Breda could earn a total revenue around 69,46 million euros. This is according to the average of the analysts' estimates. This is slightly lower than 2019's revenue of 69,78 million euros.

Historical revenues and results arGEN-X plus estimates 2020

The analysts expect for 2020 a net loss of 440 million euros. According to most of the analysts the company will have a loss per share for this book year of 9,68 euros. Based on this the price/earnings-ratio is -23,29.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 0,05 percent.

Most recent target prices around 217 euros

The most recent recommendations for the biotech company are from JP Morgan, KBC Securities and DeGroof Petercam.

Based on the current number of shares arGEN-X 's market capitalization equals 8,11 billion euros. The arGEN-X stock was the past 12 months quite volatile. Since last November the stock is even 72 percent higher. This year the stock price moved between 93 and 241 euro.

Historical stock prices arGEN-X period 2007-2020

Click here for dividend arGEN-X. At 11.27 the stock trades 1,15 percent lower at 225,4 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.